Grants and Contributions:
Title:
TRANSDUCED T CELLS FOR PRE-CLINICAL DEVELOPMENT OF NOVEL CD22 CAR-T’S
Agreement Number:
948910
Agreement Value:
$100,000.00
Agreement Date:
Apr 30, 2020 - Jan 14, 2021
Description:
This project will develop a lead candidate anti-CD22 CAR (Chimeric Antigen Receptor) comprising a camelid antibody derived anti-CD22 binding domain (developed by NRC) in the context of a CAR backbone and lentiviral vector system (developed by BC Cancer), suitable for inclusion in a CTA (Clinical Trial Application) submission to Health Canada
Organization:
National Research Council Canada
Expected Results:
In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems.
Location:
Vancouver, British Columbia, CA V5Z 4E6
Reference Number:
172-2020-2021-Q1-948910
Agreement Type:
Grant
Report Type:
Grants and Contributions
Recipient Business Number:
863530135
Recipient Type:
Not-for-profit organization or charity
Recipient's Legal Name:
BC Cancer, part of the Provincial Health Services Authority
Federal Riding Name:
Vancouver Granville
Federal Riding Number:
59036
Program:
Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
Program Purpose:
Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas.
NAICS Code:
541710 - R&D in the physical, engineering and life sciences